RO5126766

DRUG2 trials

Sponsors

Hoffmann-La Roche, Memorial Sloan Kettering Cancer Center

Conditions

Advanced Non-small Cell Lung CancerNeoplasms

Phase 1

A Dose-Escalation Study of RO5126766 in Patients With Advanced Solid Tumors.

CompletedNCT00773526

Hoffmann-La RocheNeoplasms

Start: 2008-11-30End: 2011-09-30Updated: 2016-11-02

RO5126766 for Patients With Advanced KRAS-Mutant Lung Cancer

CompletedNCT03681483

Memorial Sloan Kettering Cancer CenterAdvanced Non-small Cell Lung Cancer

Start: 2018-10-31End: 2024-07-08Updated: 2024-07-10